==== Front Immun Ageing Immun Ageing Immunity & Ageing : I & A 1742-4933 BioMed Central London 355 10.1186/s12979-023-00355-7 Research Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial Schmader Kenneth E. kenneth.schmader@duke.edu 12 Liu Christine K. 345 Flannery Brendan 6 Rountree Wes 7 Auerbach Heidi 5 Barnett Elizabeth D. 8 Schlaudecker Elizabeth P. 9 Todd Christopher A. 7 Poniewierski Marek 7 Staat Mary A. 9 Harrington Theresa 10 Li Rongxia 10 Broder Karen R. 10 Walter Emmanuel B. 711 1 grid.26009.3d 0000 0004 1936 7961 Division of Geriatrics, Department of Medicine and Center for the Study of Aging, Duke University School of Medicine, Durham, NC USA 2 grid.512153.1 Geriatric Research Education and Clinical Center (GRECC), Durham VA Health Care System, Box 3003, Durham, NC 27710 USA 3 grid.168010.e 0000000419368956 Section of Geriatrics, Division of Primary Care and Population Health, Stanford University, Stanford, CA USA 4 grid.280747.e 0000 0004 0419 2556 Geriatric Research and Education Clinical Center (GRECC), Palo Alto Veterans Affairs Health Care System, Palo Alto, CA USA 5 grid.189504.1 0000 0004 1936 7558 Geriatrics Section, Department of Medicine, School of Medicine and Boston Medical Center, Boston University, Chobanian & Avedisian, Boston, MA USA 6 grid.419260.8 0000 0000 9230 4992 Infuenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA USA 7 grid.26009.3d 0000 0004 1936 7961 Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA 8 grid.189504.1 0000 0004 1936 7558 Department of Pediatrics, Section of Pediatric Infectious Diseases, School of Medicine and Boston Medical Center, Boston University, Chobanian & Avedisian, Boston, MD USA 9 grid.24827.3b 0000 0001 2179 9593 Department of Pediatrics Division of Infectious Diseases, University of Cincinnati College of Medicine and Cincinnati Children’s Hospital and Medical Center, Cincinnati, OH USA 10 grid.416738.f 0000 0001 2163 0069 Immunization Safety Office, Centers for Disease Control and Prevention (CDC), Atlanta, GA USA 11 grid.26009.3d 0000 0004 1936 7961 Department of Pediatrics, Duke University School of Medicine, Durham, NC USA 1 7 2023 1 7 2023 2023 20 3022 9 2022 15 6 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Background Adjuvanted inactivated influenza vaccine (aIIV) and high-dose inactivated influenza vaccine (HD-IIV) are U.S.-licensed for adults aged ≥ 65 years. This study compared serum hemagglutination inhibition (HAI) antibody titers for the A(H3N2) and A(H1N1)pdm09 and B strains after trivalent aIIV3 and trivalent HD-IIV3 in an older adult population. Results The immunogenicity population included 342 participants who received aIIV3 and 338 participants who received HD-IIV3. The proportion of participants that seroconverted to A(H3N2) vaccine strains after allV3 (112 participants [32.8%]) was inferior to the proportion of participants that seroconverted after HD-IIV3 (130 participants [38.5%]) at day 29 after vaccination (difference, − 5.8%; 95%CI, − 12.9% to 1.4%). There were no significant differences between the vaccine groups in percent seroconversion to A(H1N1)pdm09 or B vaccine strains, in percent seropositivity for any of the strains, or in post-vaccination GMT for the A(H1N1)pdm09 strain. The GMTs for the post-vaccination A(H3N2) and B strains were higher after HD-IIV than after aIIV3. Conclusions Overall immune responses were similar after aIIV3 and HD-IIV3. For the primary outcome, the aIIV3 seroconversion rate for H3N2 did not meet noninferiority criteria compared with HD-IIV3, but the HD-IIV3 seroconversion rate was not statistically superior to the aIIV3 seroconversion rate. Trial registration ClinicalTrials.gov Identifier: NCT03183908. Supplementary Information The online version contains supplementary material available at 10.1186/s12979-023-00355-7. Keywords Influenza vaccine Immunogenicity Aged Adjuvanted influenza vaccine High dose influenza vaccine issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2023 ==== Body pmcBackground The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommends annual vaccination with any U.S.-licensed, age-appropriate, influenza vaccine [9]. In the U.S., two influenza vaccines licensed and recommended only for persons aged ≥ 65 years are quadrivalent high-dose inactivated influenza vaccine [HD-IIV4 (Fluzone® High-Dose Quadrivalent) (Package Insert)] [5] and quadrivalent inactivated adjuvanted influenza vaccine [aIIV4 (Fluad® Quadrivalent) (Package Insert)] [6]. At the time this study was enrolling participants, quadrivalent formulations were not yet licensed; trivalent high-dose inactivated influenza vaccine [HD-IIV3 (Fluzone® High-Dose) (Package Insert)] [7] and trivalent adjuvanted inactivated influenza vaccine [aIIV3 (Fluad®) (Package Insert)] [8] were the only U.S. influenza vaccines approved exclusively for use in persons aged ≥ 65 years. Seasonal influenza vaccines are less immunogenic in older adults compared to younger adults [3]. To improve the immunogenicity of influenza vaccines in older adults, vaccines have been developed which contain an increased the dose of hemagglutinin antigen (HD-IIV) or which contain an adjuvant (aIIV). [12, 16]. HD-IIV has four times the dose of each hemagglutinin antigen compared to standard-dose IIV (SD-IIV) [7]. Compared with SD-IIV, HD-IIV is significantly more immunogenic for the influenza A strains and noninferior for the B strains [7]. aIIV contains the MF59 adjuvant which is a squalene-based, oil-in-water emulsion [16]. Compared with SD-IIV, the MF-59 adjuvanted influenza vaccine may produce higher antibody responses and broadens the immune response to circulating influenza viruses in older adults [16]. Noninferiority of aIIV3 compared with SD-IIV3 was demonstrated for all three vaccine strains based on pre-defined thresholds for seroconversion rate differences and geometric mean titer ratios (FLUAD Package Insert). There are few data on the comparative immunogenicity of aIIV and IIV-HD in older adults. To better understand the comparative immunogenicity of these vaccines, we conducted a randomized clinical trial in older adults. The primary objective of this study was to compare seroconversion based on serum hemagglutination inhibition (HAI) antibody titer for the A (H3N2) strain after receipt of either aIIV3 or HD-IIV3 in an older adult population. A (H3N2) was chosen because this subtype is the leading cause of influenza illness and mortality in older adults [10]. We hypothesized that the seroconversion rate for the A(H3N2) strain after aIIV3 would be noninferior to HD-IIV3. Secondary objectives were to compare seroconversion rates for A(H1N1)pdm09 and B vaccine strains, and post-vaccination HAI antibody geometric mean titers (GMT) and seropositivity for each of the three influenza vaccine strains after aIIV3 or HD-IIV3 by season and age-group in the full study population. We explored associations between immunogenicity and reactogenicity, as well as between immunogenicity and age-group, sex, race, and statin use in participants receiving aIIV3 and IIV3-HD. Antibody titers for influenza vaccine antigens 6 months after vaccination were evaluated in a subset of participants. Results Study participants We assessed 778 participants for eligibility during two influenza seasons. Twenty-one participants were excluded (8 participants withdrew prior to randomization and 13 participants did not meet eligibility criteria), yielding 757 randomized participants; 378 received aIIV3 and 379 received HD-IIV3 in the full analysis population (Fig. 1). Of the 378 participants who received aIIV3, 15 had insufficient blood draws and 21 had blood draws outside the protocol-defined window, leaving 342 participants in the immunogenicity population. Of the 379 participants who received HD-IIV3, 17 had insufficient blood draws and 24 had blood draws outside the protocol-defined window, leaving 338 participants in the immunogenicity population. The baseline demographic and clinical characteristics of participants in the immunogenicity population were similar between the 2 study groups (Table 1). We randomized 279 participants in the 2017–2018 influenza season and 478 participants in the 2018–2019 influenza season. There were 45 participants in the aIIV3 group and 47 participants in the HD-IIV3 group in the subset of individuals with immune measures at 181 days post vaccination.Fig. 1 Randomization and Patient Flow in the Immunogenicity Study Comparing Trivalent Adjuvanted Inactivated Influenza Vaccine (aIIV3) vs. Trivalent High-Dose Inactivated Influenza Vaccine (HD-IIV3). The Full Analysis Population consisted of all participants who were randomized and vaccinated. The Immunogenicity Population consisted of all participants who were randomized, vaccinated and had a sufficient blood draw within the protocol defined time window Table 1 Baseline demographic and clinical characteristics of the immunogenicity population for 2017–2018 and 2018–2019 seasons Patients vaccinated, No. (%) Characteristic aIIV3a (n = 342) HD-IIV3b (n = 338) Study Site  Duke University Medical Center 191 (55.8%) 186 (55%)  Boston Medical Center 109 (31.9%) 110 (32.5%)  Cincinnati Children’s Hospital Medical Center 42 (12.3%) 42 (12.4%) Influenza Season of Enrollment  2017–2018 123 (36%) 122 (36.1%)  2018–2019 219 (64%) 216 (63.9%)  Age, median (range), y 72 (65–96) 72 (65–97) Age group, y  65–79 269 (78.7%) 261 (77.2%)   ≥ 80 73 (21.3%) 77 (22.8%)  Female 191 (55.8%) 183 (54.1%) Race  White only 258 (75.4%) 274 (81.1%)  Black only 62 (18.1%) 50 (14.8%)  Other 22 (6.4%) 14 (4.1%)  Hispanic ethnicity 7 (2%) 1 (0.3%)  Education, some college or higher 300 (87.7%) 296 (87.8%) Employment  Employed 24 (7%) 23 (6.8%)  Retired 271 (79.2%) 266 (78.7%)  None 14 (4.1%) 14 (4.1%)  Living Alone 137 (40.1%) 131 (38.8%) Cardiovascular and respiratory disorders  Atrial fibrillation 28 (7.4%) 18 (4.7%)  Coronary artery disease 23 (6.1%) 22 (5.8%)  Heart failure 20 (5.3%) 9 (2.4%)  Hyperlipidemia 124 (32.8%) 133 (35.1%)  Hypertension 76 (20.1%) 63 (16.6%)  Valvular heart disease 14 (3.7%) 10 (2.6%)  Asthma 7 (1.9%) 8 (2.1%)  Chronic obstructive pulmonary disease 6 (1.6%) 1 (0.3%) Other common conditions  Arthritis 62 (16.4%) 64 (16.9%)  Depression 45 (11.9%) 42 (11.1%)  Diabetes 19 (5.0%) 24 (6.3%)  Gastroesophageal reflux disease 35 (9.3%) 20 (5.3%)  Hearing loss 8 (2.1%) 13 (3.4%)  Hypothyroidism 35 (9.3%) 28 (7.4%)  Statin Use 168 (49.1%) 157 (46.4%)  Received influenza vaccine in the previous season 323 (94.4%) 324 (95.9%) aaIIV3: Trivalent adjuvanted inactivated influenza vaccine bHD-IIV3: Trivalent high-dose inactivated influenza vaccine Primary outcome: seroconversion rate A(H3N2) The proportion of participants that seroconverted after allV3 (112 participants [32.7%]) was inferior to the proportion of participants that seroconverted after HD-IIV3 (130 participants [38.5%]) at day 29 after vaccination (Table 2). The null hypothesis of inferiority for the aIIV3 seroconversion rate to the HD-IIV3 seroconversion rate was not rejected (p = 0.12) with a point estimate of the difference at -5.79% and associated 95% CI (-12.91%, 1.41%). Therefore, we cannot claim that the aIIV3 seroconversion rate is noninferior to HD-IIV3, but there is no statistical evidence that the HD-IIV3 seroconversion rate is superior since the confidence interval of the difference crosses zero.Table 2 Hemagglutination Inhibition (HAI) antibody titers after trivalent adjuvanted inactivated influenza vaccine (aIIV3) and trivalent high-dose inactivated influenza vaccine (HD-IIV3) for each influenza vaccine strain by season(s) 2017–2018 and 2018–2019 influenza seasons. 2017–2018 and 2018–1019 influenza seasons aIIV3 HD-IIV3 aIIV3–HD-IIV3 Strain Time N Value 95% CI N Value 95% CI Difference 95% CI 2017–2018 and 2018–1019 influenza seasons  H1N1 GMTc Day 1f 342 51.8 (44.5, 60.3) 338 50.8 (43.4, 59.4) 0.01 (-0.09, 0.10) Day 29 342 100.0 (86.6, 115.6) 338 98.0 (84.6, 113.6) 0.01 (-0.08, 0.10) %SPd Day 1 238 69.6 (64.4, 74.4) 226 66.9 (61.6, 71.8) 2.73 (-4.27, 9.72) Day 29 285 83.3 (79.0, 87.1) 282 83.4 (79.0, 87.2) -0.10 (-5.69, 5.50) %SCe Day 29 96 28.1 (23.4, 33.2) 90 26.6 (22.0, 31.7) 1.44 (-5.26, 8.14)  H3N2 GMT Day 1 342 63.4 (52.8, 76.1) 338 58.5 (48.4, 70.7) 0.03 (-0.08, 0.15) Day 29 342 141.7 (123.2, 162.9) 338 177.3 (152.7, 205.9) -0.10 (-0.19, -0.01) %SP Day 1 228 66.7 (61.4, 71.6) 222 65.7 (60.4, 70.7) 0.99 (-6.13, 8.10) Day 29 307 89.8 (86.1, 92.7) 299 88.5 (84.6, 91.6) 1.30 (-3.38, 5.99) %SC Day 29 112 32.7 (27.8, 38.0) 130 38.5 (33.2, 43.9) -5.71 (-12.90, 1.47)  Influenza B GMT Day 1 342 13.4 (11.9, 15.0) 338 14.7 (12.9, 16.7) -0.04 (-0.11, 0.03) Day 29 342 21.6 (18.5, 25.2) 338 27.5 (23.5, 32.3) -0.11 (-0.20, -0.01) %SP Day 1 84 24.6 (20.1, 29.5) 91 26.9 (22.3, 32.0) -2.36 (-8.93, 4.21) Day 29 151 44.2 (38.8, 49.6) 165 48.8 (43.4, 54.3) -4.66 (-12.15, 2.83) %SC Day 29 64 18.7 (14.7, 23.3) 79 23.4 (19.0, 28.3) -4.66 (-10.78, 1.46) 2017–2018 influenza seasona  H1N1 GMTc Day 1f 123 29.2 (23.7, 36.0) 122 29.3 (23.6, 36.5) -0.00 (-0.13, 0.13) Day 29 123 88.7 (68.5, 114.8) 122 88.6 (67.6, 116.2) 0.00 (-0.16, 0.16) %SPd Day 1 61 49.6 (40.5, 58.7) 59 48.4 (39.2, 57.5) 1.23 (-11.29, 13.75) Day 29 96 78.0 (69.7, 84.9) 100 82.0 (74.0, 88.2) -3.92 (-13.92, 6.08) %SCe Day 29 47 38.2 (29.6, 47.4) 52 42.6 (33.7, 51.9) -4.41 (-16.69, 7.87)  H3N2 GMT Day 1 123 69.7 (53.2, 91.3) 122 78.7 (59.5, 104) -0.05 (-0.22, 0.11) Day 29 123 228.2 (178.7, 291.4) 122 281.6 (213.6, 371.3) -0.09 (-0.25, 0.07) %SP Day 1 84 68.3 (59.3, 76.3) 87 71.3 (62.4, 79.1) -3.02 (-14.51, 8.47) Day 29 117 95.1 (89.7, 98.0) 108 88.5 (81.5, 93.4) 6.60 (-0.22, 13.41) %SC Day 29 55 44.7 (35.7, 53.9) 54 44.3 (35.3, 53.5) 0.45 (-11.99, 12.90)  Influenza B GMT Day 1 123 19.2 (15.9, 23.3) 122 18.9 (15.3, 23.4) 0.01 (-0.12, 0.13) Day 29 123 27.3 (21.5, 34.6) 122 37.6 (29.3, 48.3) -0.14 (-0.29, 0.01) %SP Day 1 43 35.0 (26.6, 44.1) 44 36.1 (27.6, 45.2) -1.11 (-13.09, 10.88) Day 29 62 50.4 (41.2, 59.5) 74 60.7 (51.4, 69.3) -10.25 (-22.63, 2.13) %SC Day 29 19 15.4 (9.6, 23.1) 29 23.8 (16.5, 32.3) -8.32 (-18.22, 1.57) 2018–2019 influenza seasonb  H1N1 GMTc Day 1f 219 71.5 (58.9, 86.8) 216 69.2 (56.5, 84.8) 0.01 (-0.11, 0.14) Day 29 219 107.0 (89.9, 127.5) 216 103.7 (87.1, 123.5) 0.01 (-0.09, 0.12) %SPd Day 1 177 80.8 (75.0, 85.8) 167 77.3 (71.1, 82.7) 3.51 (-4.13, 11.15) Day 29 189 86.3 (81.0, 90.5) 182 84.3 (78.7, 88.8) 2.04 (-4.62, 8.70) %SCe Day 29 49 22.4 (17.0, 28.5) 38 17.6 (12.8, 23.3) 4.78 (-2.72, 12.28)  H3N2 GMT Day 1 219 60.1 (47.1, 76.7) 216 49.5 (38.6, 63.5) 0.08 (-0.07, 0.23) Day 29 219 108.4 (92.3, 127.3) 216 136.5 (115.6, 161.2) -0.10 (-0.20, -0.00) %SP Day 1 144 65.8 (59.1, 72.0) 135 62.5 (55.7, 68.9) 3.25 (-5.76, 12.26) Day 29 190 86.8 (81.5, 90.9) 191 88.4 (83.4, 92.3) -1.67 (-7.86, 4.53) %SC Day 29 57 26.0 (20.3, 32.4) 76 35.2 (28.8, 41.9) -9.16 (-17.78, -0.54)  Influenza B GMT Day 1 219 10.9 (9.5, 12.5) 216 12.8 (10.9, 15.0) -0.07 (-0.16, 0.02) Day 29 219 19.0 (15.6, 23.1) 216 23.1 (18.9, 28.3) -0.09 (-0.21, 0.04) %SP Day 1 41 18.7 (13.8, 24.5) 47 21.8 (16.4, 27.9) -3.04 (-10.59, 4.51) Day 29 89 40.6 (34.1, 47.5) 91 42.1 (35.5, 49.0) -1.49 (-10.75, 7.77) %SC Day 29 45 20.5 (15.4, 26.5) 50 23.1 (17.7, 29.3) -2.60 (-10.36, 5.16) aVirus strains H1N1: A/Michigan/45/2015 (H1N1) pdm09-like virus; H3N2: A/Hong Kong /4801/2014 (H3N2)-like virus; B: B/Brisbane/60/2008-like virus (Victoria lineage) bVirus strains H1N1: A/Michigan/45/2015 (H1N1)pdm09-like virus; H3N2: A/Singapore/INFIMH-16–0019/2016 A(H3N2)-like virus; B: B/Colorado/06/2017-like virus (Victoria lineage) cGMT: Geometric mean titers d%SP: Percent Seropositive, defined as HAI titer ≥ 1:40 e%SC: Percent Seroconversion, defined as an HAI titer ≥ 1:40 at day 29 post-vaccination if the baseline pre-vaccination titer is < 1:10 or a minimum four-fold rise in HAI titer if the baseline pre-vaccination titer is ≥ 1:10 fDay 1: Baseline blood draw before vaccination; Day 29 blood draw on 29 ± 7 days post-vaccination Secondary outcomes For the H3N2 strain, there were no significant differences in the percent seropositive between the aIIV3 and HD-IIV3 groups for all ages or for either age group 65 to 79 years and 80 years and older (Tables 2 and 3). There was no difference (aIIV3 minus HD-IIV3), in Day 29 GMTs for the ≥ 80-year group but there was a difference for all ages (GMT aIIV3, 141.7 vs. IIV-HD, 177.3; difference, -0.10 (95% CI, -0.19, -0.01)) and the 65–79-year age group (GMT aIIV3, 145.3 vs. IIV3-HD, 184.4; difference -0.10 (95% CI, -0.20, -0.00); Tables 2 and 3). A difference was observed in the rate of seroconversion between the treatment groups in the 2018–2019 season (aIIV3, 26.0% vs. HD-IIV3, 35.2%; difference -9.16 (95% CI -17.78, -0.54)) whereas there was no difference between the groups in the 2017–2018 season (aIIV3, 44.7% vs. HD-IIV3, 44.3%; difference 0.45 (95% CI -11.99, 12.90); Table 2). Reverse cumulative distribution curves summarizing participants HAI titer results from both seasons for influenza H3N2, H1N1 and B for each treatment group are shown in Supplementary Fig. 1.Table 3 Hemagglutination Inhibition (HAI) antibody titers after trivalent adjuvanted inactivated influenza vaccine (aIIV3) and trivalent high-dose inactivated influenza vaccine (HD-IIV3) for each influenza vaccine strain by age for 2017–2018 and 2018–2019 influenza seasons 65–79 Years aIIV3 Group HD-IIV3 Group aIIV3–HD-IIV3 Strain Time N Value 95% CI N Value 95% CI Difference 95% CI  H1N1 GMTa Day 1d 269 52.5 (44.3, 62.2) 261 49.5 (41.4, 59.0) 0.03 (-0.08, 0.13) Day 29 269 108.8 (92.1, 128.5) 261 100.9 (84.9, 119.9) 0.03 (-0.07, 0.14) %SPb Day 1 188 69.9 (64.0, 75.3) 171 65.5 (59.4, 71.2) 4.37 (-3.59, 12.33) Day 29 225 83.6 (78.7, 87.8) 216 82.8 (77.6, 87.1) 0.88 (-5.48, 7.25) %SCc Day 29 80 29.7 (24.3, 35.6) 71 27.2 (21.9, 33.0) 2.54 (-5.14, 10.22)  H3N2 GMT VDay 1 269 63.3 (51.7, 77.5) 261 56.4 (45.5, 69.8) 0.05 (-0.08, 0.18) Day 29 269 145.3 (124.3, 169.7) 261 184.4 (155.2, 219.1) -0.10 (-0.20, -0.00) %SP Day 1 181 67.3 (61.3, 72.8) 171 65.5 (59.4, 71.2) 1.77 (-6.27, 9.81) Day 29 246 91.4 (87.4, 94.4) 230 88.1 (83.6, 91.7) 3.33 (-1.83, 8.48) %SC Day 29 92 34.2 (28.5, 40.2) 103 39.5 (33.5, 45.7) -5.26 (-13.47, 2.94)  Influenza B GMT Day 1 269 12.2 (10.8, 13.8) 261 11.8 (10.3, 13.4) 0.02 (-0.06, 0.09) Day 29 269 20.3 (17.2, 24.1) 261 23.8 (20.0, 28.4) -0.07 (-0.17, 0.04) %SP Day 1 60 22.3 (17.5, 27.8) 52 19.9 (15.3, 25.3) 2.38 (-4.56, 9.33) Day 29 114 42.4 (36.4, 48.5) 118 45.2 (39.1, 51.5) -2.83 (-11.28, 5.61) %SC Day 29 51 19.0 (14.5, 24.2) 68 26.1 (20.8, 31.8) -7.09 (-14.19, -0.00) 80 years and older  H1N1 GMTa Day 1d 73 49.3 (35.1, 69.3) 77 55.6 (39.2, 78.8) -0.05 (-0.26, 0.16) Day 29 73 73.4 (55.2, 97.7) 77 88.7 (66.7, 118.0) -0.08 (-0.25, 0.09) %SPb Day 1 50 68.5 (56.6, 78.7) 55 71.4 (60.0, 81.0) -2.94 (-17.61, 11.74) Day 29 60 82.2 (71.5, 89.9) 66 85.7 (75.9, 92.4) -3.52 (-15.27, 8.23) %SCc Day 29 16 21.9 (13.1, 33.1) 19 24.7 (15.6, 35.8) -2.76 (-16.28, 10.76)  H3N2 GMT Day 1 73 63.7 (41.4, 98.0) 77 66.5 (43.9, 101) -0.02 (-0.27, 0.24) Day 29 73 129.2 (93.4, 178.8) 77 155.0 (114.2, 210.5) -0.08 (-0.27, 0.11) %SP Day 1 47 64.4 (52.3, 75.1) 51 66.2 (54.6, 76.5) -1.85 (-17.09, 13.39) Day 29 61 83.6 (73.0, 91.0) 69 89.6 (80.6, 95.2) -6.05 (-16.95, 4.85) %SC Day 29 20 27.4 (17.6, 39.1) 27 35.1 (24.5, 46.7) -7.67 (-22.44, 7.11)  Influenza B GMT Day 1 73 18.7 (14.6, 24.0) 77 31.2 (23.2, 42.1) -0.22 (-0.39, -0.05) Day 29 73 27.0 (19.0, 38.2) 77 45.0 (31.8, 63.5) -0.22 (-0.43, -0.01) %SP Day 1 24 32.9 (22.3, 44.8) 39 50.6 (39.0, 62.2) -17.77 (-33.29, -2.25) Day 29 37 50.7 (38.7, 62.5) 47 61.0 (49.2, 71.8) -10.35 (-26.17, 5.46) %SC Day 29 13 17.8 (9.8, 28.5) 11 14.3 (7.4, 24.1) 3.52 (-8.23, 15.27) a GMT: Geometric mean titers b % SP: Percent Seropositive, defined as HAI titer ≥ 1:40 c % SC: Percent Seroconversion, defined as an HAI titer ≥ 1:40 at day 29 post-vaccination if the baseline pre-vaccination titer is < 1:10 or a minimum four-fold rise in HAI titer if the baseline pre-vaccination titer is ≥ 1:10 d Day 1: Baseline blood draw before vaccination; Day 29 blood draw on 29 ± 7 days post-vaccination For the A(H1N1)pdm09 and B strains there were no significant differences in percent seroconversion, Day 29 GMTs, and percent seropositive between the aIIV3 and HD-IIV3 groups for all ages (Table 2) or by age groups 65 to 79 years and 80 years and older, with two exceptions for the B strain (Table 3). The seroconversion for the B strain was significantly higher after HD-IIV-3 vs. aIIV3-HD in the 65–79 age group and the Day 29 GMT in the ≥ 80 age group was significantly higher after HD-IIV3 vs. aIIV3. Exploratory outcomes We found no relationship between HAI titer and at least one moderate/severe reactogenicity event (n = 146, 19.9%) for allV3 and HD-IIV3 treatment groups. There were statistically significant associations for sex and ethnicity for H1N1; treatment group, site, and year of study for H3N2; and sex, age, and year of study for influenza B and HAI titers (Table 4). For the subset of participants with serum collection 6 months post-vaccination, Fig. 2 shows changes in HAI GMT and percent seropositive at 29 days and 181 days after aIIV3 (n = 45) and HD-IIV3 (n = 47). There were no statistically significant differences between vaccine groups for any strain at 29 and 181 days post-vaccination at the 0.05 alpha level. Supplement Table 2 shows HAI GMT, seropositivity (SP) and seroconversion (SC) rates after aIIV3 and HD-IIV3 for each influenza vaccine strain at Day 1 (before vaccination) and Day 29 and Day 181 post-vaccination.Table 4 Significant associations between hemagglutination Inhibition (HAI) titers and demographic measures (age, gender, race, ethnicity), site, treatment group, year of study, and statin use assessed using a linear regression modela Influenza Vaccine Strain Measure Median Titer GMTb p-value  H1N1 Sex 0.0245 Male 80 100.9 Female 160 127.3 Ethnicity 0.0196 Hispanic 96.6 109.1 Non-Hispanic 80 85.4 Other 160 156.4  H3N2 Treatment Group 0.0145 allV3 160 257.8 HD-IIV3 160 326.5 Site 0.0010 Boston Medical Center 160 226.1 Cincinnati Children’s Hospital 160 446.4 Duke University 160 241.9 Year of Study  < 0.0001 2017–2018 320 452.2 2018–2019 160 186.1  Influenza B Gender 0.0025 Male 40 28.9 Female 20 20.8 Age Group 0.0001 65–79 20 18.7 80 +  40 32.2 Year of Study  < 0.0001 2017–2018 40 32.6 2018–2019 20 18.5 aAny of the independent variables (age, gender, race, ethnicity), site, treatment group, year of study, and statin use not presented per influenza strain were not significant in these regression analyses bThe GMTs for each outcome measure are adjusted in the model based on the other covariates Fig. 2 Mean hemagglutinin inhibition (HAI) geometric mean titers (GMT) and percent seropositive (% SP) (HAI titer ≥ 1:40) in the adjuvanted inactivated influenza (aIIV3) (n = 45) and high-dose inactivated influenza (HD-IIV3) (n = 47) groups for H1N1, H3N2 and B strains at Day 1 pre-vaccination and Day 29 and Day 181 post-vaccination Discussion This is the first randomized clinical trial in the United States directly comparing immunogenicity following vaccination with aIIV3 or HD-IIV3 in older adults. For the primary outcome, we hypothesized that the seroconversion rate for the A(H3N2) strain after aIIV3 would be noninferior to HD-IIV3. We found that the proportion of participants that seroconverted at day 29 after vaccination after allV3 (32.8%) was statistically inferior to the proportion of participants that seroconverted after HD-IIV3 (38.4%) using a 10% noninferiority margin. The clinical significance of this finding is unclear. The difference in proportions (5.8%) between the groups was small. The difference in the rate of seroconversion between groups occurred only for the 2018–2019 season and not for the 2017–2018 season. The seropositive rates at day 29 post-vaccination for A(H3N2) were very high in both groups (aIIV3, 89.8%; HD-IIV3, 88.5%). There were no significant differences observed in GMTs at 29 days after vaccination in treatment groups after H1N1 or after B in the older age group; GMTs were significantly higher after HD-IIV3 vs. aIIV3 in the 65–79 age group. Furthermore, the proportion of subjects achieving seroconversion, for the H1N1 and influenza B vaccine strains showed no significant differences between the aIIV3 and HD-IIV3 vaccinated groups. In a post licensure study in Hong Kong conducted during the 2017–2018 influenza season, Cowling et al. compared immune responses to aIIV3 (n = 200), HD-IIV3 (n = 200), and trivalent recombinant influenza vaccine (RIV3) (n = 200) with SD-IIV4 (n = 200) in community dwelling adults aged 65–82 years [2]. Authors observed no significant differences between aIIV3 and HD-IIV3 groups in HAI GMTs, mean fold rise, or percent with ≥ fourfold rise at day 30 post-vaccination for any vaccine strain. The proportion of participants with an HAI titer ≥ 1:40 at 30 days was 96% in the aIIV3 group and 96% in the HD-IIV3 group. We explored whether a more robust immune response to either influenza vaccine was associated with increased reactogenicity. As there were few grade 3 (severe) reactions, analysis of the relationship between severe reactions and immune response was not possible. Instead, we combined moderate and severe reactions (19.9% of participants) and found no association between the magnitude of serologic immune responses and the occurrence of at least one moderate/severe reactogenicity event for either of the treatment groups. In a study of adjuvanted H1N1 influenza vaccine in 178 heathy participants aged 18–65 years old, 23% of individuals developed moderate-severe adverse events (local or systemic) [15]. The study found no correlation between these adverse events and serological vaccine response as measured by HAI and microneutralization assays. Thus, the data suggest that the severity of local or systemic reactions is not associated with the magnitude of the serologic immune response to influenza vaccine, but the topic deserves further study. After adjusting for site, age group, treatment group, sex, race, and ethnicity our models found no effect of current statin use on HAI titers compared to no use of statins. This finding differs from that of a cross-sectional observational study of statin therapy on the immune response to influenza vaccine in 6961 subjects aged 65 years and older, which was nested within a comparative immunogenicity clinical trial of adjuvanted versus unadjuvanted influenza vaccine [1]. In that study, HAI GMTs to influenza A(H1N1)pdm09, A(H3N2), and B strains were significantly lower at 22 days post-vaccination in subjects receiving statin therapy, defined as taking statins from ≥ 28 days before through 22 days after vaccination, compared with those not receiving statin therapy. However, this finding was limited by using self-report for statin use and lack of detail on statin dose and duration of therapy. In a subset of participants assessed for waning immunity 6 months after vaccination in season 1, the proportion of participants with seropositivity remained higher 6 months after vaccination than at baseline for H3N2 and H1N1 A strains; > 60% of participants had seropositivity at 6 months post-vaccination for these strains. The mean GMTs for the A strains were also higher at 6 months vs at baseline. Immunogenicity was lower for the B strains for both vaccines, and at 6 months the proportion of participants with seropositivity and mean GMTs were similar to baseline. This study is subject to some limitations. The study population was drawn from a population of community-dwelling older adults, who were generally healthy, mostly white, and well educated (> 85% had some college education or more), and therefore not representative of less well, frail, non-white, lower-educated older adults. The study included only two influenza seasons. There were no measures of cellular immunity. Although we used standard serological measures of immune response to influenza vaccine, antibody responses appear to be less reliable measures of protection in older adults with multiple co-morbidities or frailty compared to measures of cellular immunity [13]. HAI titers are also not a direct measure of influenza vaccine effectiveness. Although HAI titers may be a correlate of protection for influenza illness in older adults, individual post vaccination titers do not reliably classify a person as protected [4, 17]. Conclusion In our trial comparing aIIV3 and HD-IIV3 in older adults, overall immunogenicity findings were similar after aIIV3 and HD-IIV3. For the primary outcome of seroconversion for H3N2, the aIIV3 seroconversion rate was inferior to HD-IIV3, but the HD-IIV3 seroconversion rate was not statistically superior to the aIIV3 seroconversion rate. Methods Study design and population We conducted a prospective, randomized, blinded clinical trial at CDC-sponsored Clinical Immunization Safety Assessment (CISA) Project sites during the 2017–2018 (Duke University Medical Center and Boston Medical Center) and 2018–2019 (Duke, Boston, and Cincinnati Children’s Hospital Medical Center) influenza seasons. The study protocol was approved by institutional review boards at each study site and was registered at ClinicalTrials.gov (NCT03183908); CDC relied on the Duke institutional review board. We previously described design and safety outcomes from this study [14]. In brief, the eligibility criteria included age ≥ 65 years, community-dwelling, not immunosuppressed, cognitively intact, able to speak English, and no contraindications to influenza vaccination [14]. We aimed to have at least 20% of the study population to be ≥ 80 years old. After obtaining written informed consent on Day 1, staff collected demographic, medical history, and medication information on each eligible participant. Participants had blood drawn for antibody studies on Day 1 (vaccination day) before vaccination and on Day 29 ± 7 days post-vaccination. At the Duke site only, a convenience sample of participants had blood drawn on Day 181 ± 14 days in year one. At enrollment, participants were randomized (1:1) to receive aIIV3 or HD-IIV3 using a permuted block randomization scheme stratified by study site. Separate permuted blocks were used for participants aged 65 − 79 and ≥ 80 years. Participants and study staff performing data collection and analysis were blinded to treatment allocation. Following randomization, a 0.5 mL intramuscular dose of either U.S.-licensed aIIV3 or HD-IIV3 was administered in the deltoid muscle by a designated unblinded vaccinator, who did not participate in other aspects of the study. Each aIIV3 dose contained 15 mcg of hemagglutinin (HA) from each of the three recommended influenza strains for the respective season and MF59 adjuvant, a squalene-based, oil-in-water emulsion. Each HD-IIV3 dose contained 60 mcg of HA from each of the three recommended influenza strains for the respective season (Supplement Table 1) [14]. Laboratory methods Influenza hemagglutination inhibition (HAI) assay Reference vaccine virus strains (Supplement Table 1) representative of the specific viral antigens included in the 2017–2018 and 2018–2019 influenza vaccines and propagated in embryonated chicken eggs were used to evaluate the relative levels of all three influenza strain-specific antibodies in participant serum samples. The HAI assay was performed in accordance with the Duke Regional Biocontainment Laboratory Virology Unit’s fully optimized and approved protocol (RVUSOP004 Influenza HI of Serum Samples). Test samples were assayed by HAI as duplicate twofold dilution series starting at 1:10. Serum dilutions are then incubated with a concentration of virus verified to possess a known potential for red blood cell (RBC) agglutination. The presence of virus-specific antibodies was visualized via incubation of the virus-serum mixture with RBC solution; the endpoint titer for a given dilution series was then expressed as the reciprocal of the final dilution in which complete HAI is observed. By convention, seronegative samples are defined as having an endpoint HAI titer < 40. Seropositive samples are defined as having an endpoint titer of ≥ 1:40. Seroconversion is defined as an HAI titer ≥ 1:40 at day 29 post-vaccination if the baseline pre-vaccination titer is < 1:10 or a minimum four-fold rise in HAI titer if the baseline pre-vaccination titer is ≥ 1:10 [11]. Outcome measures The primary outcome was the proportion of subjects achieving A(H3N2) seroconversion at day 29 for the respective season’s vaccine component. Secondary outcomes included the proportion of subjects achieving seroconversion at day 29 for A(H1N1)pdm09 or B strains, proportions of subjects in each age group achieving seroprotection at day 29 for A(H3N2), A(H1N1)pdm09 or B strains, proportions of subjects achieving post-vaccination HAI titer ≥ 1:40 for each season’s vaccine strains, and post-vaccination HAI geometric mean titers (GMT). Exploratory outcomes included associations between HAI titers and moderate/severe local and systemic reactogenicity events as the dependent variable [14]. Exploratory outcomes also included associations between age, sex, race, ethnicity, and statin use and HAI titers as the dependent variable. We assessed changes in HAI titers from baseline and at 181 days post-vaccination in a subset of subjects at the Duke study site only during the 2017–2018 season study year. Statistical analysis The planned sample size of at least 780 evaluable participants (390 per group across all sites).provided approximately 80% power to reject the null hypothesis that the proportion of participants that seroconverted at day 29 for the A(H3N2) strain after aIIV3 is inferior to HD-IIV3 assuming a 50% seroconversion rate. The statistical testing for the primary immunogenicity outcome was conducted at the 1-sided α = 0.025 level using the upper bound of a Newcombe binomial confidence interval [18] stratified by study site with Cochran-Mantel–Haenszel (CMH) weighting with a noninferiority margin of 10%. Comparisons of seropositivity and seroconversion rates were made using the immunogenicity population that consisted of all participants who were randomized, vaccinated, and provided baseline and day 29 post-immunization blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity. The comparison of seropositivity and seroconversion rates (with the exception of the primary outcome above) between treatment groups was made using exact binomial 95% CIs. We calculated the 95% CI on the difference between mean proportions for seropositivity and seroconversion rates and log10 transformed GMTs between treatment groups (aIIV3 minus HD-IIV3); a difference that did not cross 0 was considered a statistically significant difference. The relationship between immunogenicity and reactogenicity for allV3 and HD-IIV3 was assessed using a logistic regression model with at least one moderate/severe reactogenicity event as the dependent variable and covariates of the post-vaccination strain-specific log10 HAI titer, site, age group and treatment group. The assessment of factors associated with immunogenicity for allV3 and HD-IIV3 was made with a linear regression model with the log10 HAI titer as the dependent variable with site, age group, treatment group, sex, ethnicity, race, year of study, and statin use as covariates. The comparison of seropositivity and seroconversion rates and changes in serum hemagglutination inhibition at one month and six months after vaccination were made using a Cochran-Mantel–Haenszel test. The exploratory objectives described above included participants who were randomized, vaccinated, and had complete immunologic data. We used a 2-sided α = 0.05 level for all the exploratory analyses with no adjustment for multiple comparisons. These data were analyzed using SAS statistical software version 9.4 (SAS Institute). Supplementary Information Additional file 1: Supplementary Figure 1. Reverse cumulative distribution curves summarizing participants HAI titer results from both seasons for influenza H3N2, H1N1 and B for each treatment group. Additional file 2: Supplementary Table 1. Virus strains in the trivalent adjuvanted inactivated influenza vaccine (aIIV3), the trivalent high dose inactivated influenza vaccine (HD-IIV3) and the influenza hemagglutination inhibition assay test viruses, 2017-2018 and 2018-2019 influenza seasons. Supplementary Table 2.Hemagglutination Inhibition (HAI) geometric mean antibody titers (GMT) and sero-protection (SP) and seroconversion (SC) rates after aIIV3 (n=45) and HD-IIV3 (n=47) for each influenza vaccine strain at Day 1 (before vaccination) and Day 29 and Day 181 post-vaccination for 2017-2018 influenza season. Acknowledgements The authors acknowledge the contributions of the study participants and staff; from the CDC, Frank DeStefano, MD, MPH, Lisa Grohskopf, MD, MPH, Oidda Museru, MSN, MPH, Alicia Fry, MD, MPH, Tom Shimabukuro MD, MPH, MBA, Pedro Moro, MD, MPH, Devindra Sharma, MSN, MPH, Patricia Wodi, MD; from Duke, Sue Doyle, Kristen Gunnell, Joyce Gandee; from Boston Medical Center, Anisha Bhanot, Elizabeth Liu, Dayeun Lee, Jordan Detrick, and Maria Narvaez and the nurses and office staff at Boston Medical Center Geriatric Clinic; from Cincinnati Children’s Hospital and Medical Center, Nancy Black, Brittney Cassell, and Krista Doerflein. Disclaimer The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Authors’ contributions KES, CKL,WR, HA, EDB, CAT, MP, TH, KRB and EBW made substantial contributions to the conception and design of the work; and the acquisition, analysis, and interpretation of data; All authors made substantial contributions to the interpretation of the data and have drafted the work or substantively revised it. All authors have approved the submitted version and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. Dr. Schmader had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. WR and MP conducted and are responsible for the data analysis. Funding This work was supported by the Centers for Disease Control and Prevention (Clinical Immunization Safety Assessment (CISA) Project Contract [200–2012-53663/0008 and 200–2012-53663/0015] to Duke University and Contract [200–2012-53709] to Boston University. The role of the funder included providing input on all aspects of the design and conduct of the study; analysis, preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Availability of data and materials Individual deidentified participant data will not be shared. Declarations Ethics approval and consent to participate The study protocol was approved by institutional review boards at each study site and was registered at ClinicalTrials.gov (NCT03183908); CDC relied on the Duke institutional review board. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. ==== Refs References 1. Black S Nicolay U Del Giudice G Rappuoli R Influence of statins on influenza vaccine response in elderly individuals J Infect Dis 2016 213 1224 1228 10.1093/infdis/jiv456 26516142 2. Cowling BJ Perera RAPM Valkenburg SA Leung NHL Iuliano AD Tam YH Wong JHF Fang VJ Li APY So HC Ip DKM Azziz-Baumgartner E Fry AM Levine MZ Gangappa S Sambhara S Barr IG Skowronski DM Peiris JSM Thompson MG Comparative immunogenicity of several enhanced influenza vaccine options for older adults: A randomized, controlled trial Clin Infect Dis 2020 71 7 1704 1714 10.1093/cid/ciz1034 31828291 3. Dugan HL Henry C Wilson PC Aging and influenza vaccine-induced immunity Cell Immunol 2020 348 103998 10.1016/j.cellimm.2019.103998 31733824 4. Dunning AJ DiazGranados CA Voloshen T Hu B Landolfi V Talbot HK Correlates of protection against influenza in the elderly: results from an influenza vaccine efficacy trial Clin Vaccine Immunol 2016 23 228 235 10.1128/CVI.00604-15 26762363 5. FLUZONE High-Dose Quadrivalent Sanofi Pasteur. US Package Insert, 2020 https://www.fda.gov/media/132238/download 6. FLUAD® QUADRIVALENT Seqirus Inc. US Package Insert, 25 June 2020 https://www.fda.gov/media/135432/download 7. FLUZONE High-Dose Sanofi Pasteur. US Package Insert, 2019 https://www.fda.gov/media/119870/download 8. FLUAD® Seqirus Inc. US Package Insert, 2019 https://www.fda.gov/media/94583/download 9. Grohskopf LA Alyanak E Ferdinands JM Broder KR Blanton LH Talbot HK Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices — United States, 2021–22 influenza season MMWR Recomm Rep 2021 70 No. RR-5 1 28 10.15585/mmwr.rr7005a1 34448800 10. Jester BJ Uyeki TM Jernigan DB Fifty years of influenza A (H3N2) following the pandemic of 1968 Am J Public Health 2020 110 669 676 10.2105/AJPH.2019.305557 32267748 11. Katz JM Hancock K Xu X Serologic assays for influenza surveillance, diagnosis and vaccine evaluation Expert Rev Anti Infect Ther 2011 9 669 683 10.1586/eri.11.51 21692672 12. Keitel WA Atmar RL Cate TR Peterson NJ Greenberg SB Ruben F Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons Arch Intern Med 2006 166 1121 1127 10.1001/archinte.166.10.1121 16717175 13. McElhaney JE Verschoor CP Andrew MK Haynes L Kuchel GA Pawelec G The immune response to influenza in older humans: beyond immune senescence Immunity Ageing 2020 17 1 10 10.1186/s12979-020-00181-1 31911808 14. Schmader KE Liu CK Harrington T Rountree W Auerbach H Walter EB Safety, reactogenicity, and health-related quality of life after trivalent adjuvanted versus trivalent high-dose inactivated influenza vaccines in older adults. A randomized clinical trial JAMA Open Netw 2021 4 1 e2031266 10.1001/jamanetworkopen.2020.31266 15. Sobolev O Binda E O’Farrell S Lorenc A Pradines J Huang Y Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events Nat Immunol 2016 17 204 213 10.1038/ni.3328 26726811 16. Tsai TF Fluad(R)-MF59(R)-adjuvanted influenza vaccine in older adults Infect Chemother 2013 45 159 174 10.3947/ic.2013.45.2.159 24265964 17. Verschoor CP Andrew MK Loeb M Pawlec G Haynes L Kuchel GA McElhaney JE Antibody and cell-mediated immune responses are correlates of protection against influenza in vaccinated older adults Vaccines 2021 9 25 10.3390/vaccines9010025 33430191 18. Yan X Su X Stratified Wilson and Newcombe confidence intervals for multiple binomial proportions Stat Biopharm Res 2010 2 3 329 335 10.1198/sbr.2009.0049